loading...| Preferred Name |
Nomacopan |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167012 |
| CAS_Registry |
875125-19-2 |
| code |
C167012 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 |
| Contributing_Source |
CTRP FDA |
| DEFINITION |
A recombinant small peptide inhibitor of the terminal complement pathway protein C5 originally derived from a protein in the saliva of the Ornithodoros moubata tick, with potential anti-inflammatory and cytoprotective activities. Upon administration, nomacopan targets and binds to a unique site on the terminal complement protein C5, which blocks C5 cleavage into the pro-inflammatory components C5a and C5b, and prevents the C5b-dependent assembly of the membrane-attack complex (MAC; C5b-9). This prevents MAC-mediated lysis and destruction of red blood cells (RBCs) in paroxysmal nocturnal hemoglobinuria (PNH) and prevents tissue destruction in various other complement-mediated inflammatory and autoimmune diseases. In addition, this C5 inhibitor targets, binds to and inhibits the activity of leukotriene B4 (LTB4), thereby further preventing inflammatory-mediated cell destruction. |
| Display_Name |
Nomacopan |
| FDA_UNII_Code |
79V7Q9VIWQ |
| FULL_SYN |
Recombinant EV576 Complement C5-inhibitor rEV576 Recombinant OmCI Recombinant Ornithodoros moubata Saliva-derived Small Protein Complement C5 Inhibitor rEV576 Coversin Recombinant Ornithodoros moubata Complement Inhibitor NOMACOPAN Nomacopan |
| label |
Nomacopan |
| NCI_Drug_Dictionary_ID |
795332 |
| NCI_META_CUI |
CL972006 |
| Preferred_Name |
Nomacopan |
| prefixIRI |
Thesaurus:C167012 |
| prefLabel |
Nomacopan |
| Semantic_Type |
Pharmacologic Substance |
| subClassOf |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C574 |
| Delete | Mapping To | Ontology | Source |
|---|---|---|---|
| There are currently no mappings for this class. | |||